In immunocompetent mouse models of lung adenocarcinoma, TIM-3 has been found to be upregulated following PD-1 blockade with anti-TIM-3 antibody, resulting in a survival advantage [35]. Here, HAVCR2 is linked to lung adenocarcinoma.